By Counterforce Health Team in Rezlidhia (olutasidenib) —

How to Get Rezlidhia (olutasidenib) Covered by Cigna in Texas: Appeals Guide with State Protections

Answer Box: Getting Rezlidhia (olutasidenib) Covered by Cigna in Texas

Eligibility: Adults with relapsed/refractory AML and confirmed IDH1 mutation via FDA-approved diagnostic test, prescribed by a board-certified oncologist.

Fastest Path: Your oncologist submits complete prior authorization to Cigna with IDH1 mutation results (FDA-approved test), medical necessity letter citing NCCN guidelines, and detailed treatment history showing relapse/refractory status.

First Step Today: Call Cigna Customer Service at 1-800-882-4462 to confirm current PA requirements and submission method. Ensure your IDH1 test results specify FDA-approved diagnostic status—research-use-only tests will result in automatic denial.

Texas Advantage: Strong step therapy override protections and binding external review through Independent Review Organizations if appeals are needed.

Table of Contents

  1. Why Texas State Rules Matter
  2. Cigna Prior Authorization Requirements
  3. Texas Step Therapy Protections
  4. Appeals Process and Timelines
  5. External Review Through Texas Department of Insurance
  6. Common Denial Reasons and Solutions
  7. Practical Scripts and Templates
  8. Cost Savings and Patient Support
  9. When to Escalate to State Regulators
  10. Frequently Asked Questions

Why Texas State Rules Matter

Texas provides some of the strongest patient protections for specialty drug coverage in the nation. While Cigna operates under federal regulations for many employer plans, state-regulated plans (look for "TDI" on your insurance card) benefit from specific Texas laws that can override restrictive insurer policies.

Key Texas Advantages:

  • Step therapy override requirements with specific medical exception criteria
  • Binding external review through Independent Review Organizations
  • Continuity of care protections during plan transitions
  • Expedited review timelines for urgent cases

For Rezlidhia (olutasidenib), these protections are particularly valuable given the drug's high cost (~$32,000/month) and the urgent nature of relapsed/refractory AML treatment.

Cigna Prior Authorization Requirements

Coverage at a Glance

Requirement Details Documentation Needed
Age 18+ years Date of birth verification
Diagnosis Relapsed/refractory AML ICD-10 codes, pathology reports
Mutation Status IDH1 mutation confirmed FDA-approved diagnostic test results
Prescriber Board-certified oncologist/hematologist Provider credentials
Maximum Dose 300 mg/day Dosing justification if higher
Processing Time 72 hours standard, 24 hours expedited Complete submission required

Critical Documentation Requirements

IDH1 Mutation Testing: Cigna requires results from an FDA-approved diagnostic test such as the Abbott RealTime IDH1 CDx. Research-use-only tests or non-FDA-approved assays will result in automatic denial, even if they detect the same mutation.

Medical Necessity Letter Must Include:

  • NCCN guideline citations for IDH1-mutated AML
  • Complete prior treatment history with dates, doses, and outcomes
  • Documentation of relapse or refractory status
  • Monitoring plan for differentiation syndrome and hepatic toxicity
  • Clinical rationale for Rezlidhia over alternatives

Submission Process

  1. Call Cigna at 1-800-882-4462 to confirm current requirements
  2. Submit via correct pathway (provider portal or precertification line)
  3. Include all required attachments in initial submission
  4. Request expedited review if clinically urgent

Texas Step Therapy Protections

Texas Insurance Code Chapter 1369 provides strong protections against inappropriate step therapy requirements for oncology medications.

Medical Exception Criteria

Under Texas law, Cigna must grant a step therapy override when your prescribing provider documents any of the following:

  • Contraindication: The required first-line drug is contraindicated or will likely cause harm
  • Previous failure: You've previously tried and failed the required drug or one with the same mechanism
  • Expected ineffectiveness: The required drug is expected to be ineffective based on your clinical characteristics
  • Treatment delay concern: The step therapy protocol would cause harm or be ineffective

Override Timeline Requirements

  • Non-urgent requests: 72 hours for response
  • Urgent requests: 24 hours for response
  • Automatic approval: If Cigna fails to respond within required timeframe
From our advocates: "We've seen several cases where patients were initially denied Rezlidhia due to step therapy requirements, but Texas law provided a clear path to override. The key is having your oncologist document that standard chemotherapy regimens were previously tried and failed—this typically results in rapid approval under the 'previous failure' criteria."

Appeals Process and Timelines

Internal Appeals with Cigna

First-Level Internal Appeal:

  • Deadline: 180 days from denial notice
  • Timeline: 30 days for pre-service, 60 days for post-service
  • Expedited: 72 hours for urgent cases
  • Submission: Written request explaining why coverage should be approved

Required Appeal Documentation:

  • Original denial letter
  • Updated medical necessity letter
  • Additional clinical evidence supporting coverage
  • NCCN guideline references
  • Peer-reviewed literature on IDH1-targeted therapy

Texas External Review Process

If Cigna denies your internal appeal, Texas provides binding external review through Independent Review Organizations (IROs).

External Review Timeline:

  • File within: 4 months of final internal denial
  • Standard review: 20 days for decision
  • Expedited review: 3-5 days for urgent cases
  • Cost: Paid by Cigna, free to patients

To Request External Review:

  1. Contact Texas Department of Insurance at 1-800-252-3439
  2. Submit IRO request form provided with denial notice
  3. Include all medical records and supporting documentation
  4. Request expedited review if treatment delay would jeopardize health

The IRO decision is binding—if reviewers overturn the denial, Cigna must provide coverage.

Common Denial Reasons and Solutions

Denial Reason Solution Required Documentation
IDH1 mutation not documented Submit FDA-approved test results Abbott RealTime IDH1 CDx report
Not relapsed/refractory Provide treatment history Prior therapy dates, responses, toxicities
Non-oncology prescriber Transfer to hematologist/oncologist Board certification verification
Lack of monitoring plan Submit detailed monitoring protocol Differentiation syndrome, hepatic function plans
Step therapy required Request Texas override Previous failure documentation
Non-formulary status Request formulary exception Medical necessity, alternative failures

Practical Scripts and Templates

Patient Phone Script for Cigna

"Hello, I'm calling about prior authorization for Rezlidhia, generic name olutasidenib, for my relapsed AML with IDH1 mutation. My oncologist needs to submit a PA request. Can you please confirm:

  • The current PA form and submission method
  • Required attachments and documentation
  • Expected processing timeline
  • Whether expedited review is available My member ID is [number] and I'm calling from Texas."

Clinician Peer-to-Peer Request Script

"I'm requesting a peer-to-peer review for olutasidenib coverage denial. My patient has relapsed/refractory AML with confirmed IDH1 mutation via FDA-approved testing. They've failed [list prior therapies] and meet NCCN criteria for IDH1-targeted therapy. Under Texas Insurance Code Chapter 1369, step therapy should be overridden due to previous treatment failures. When can we schedule the peer-to-peer review?"

Cost Savings and Patient Support

Manufacturer Support Programs

Rigel Pharmaceuticals Patient Support:

  • Copay assistance for eligible patients
  • Prior authorization support services
  • Financial hardship programs
  • Bridge therapy during appeals

Contact: Verify current program details with Rigel Pharmaceuticals

Additional Resources

  • CancerCare Financial Assistance: Copay and travel grants
  • HealthWell Foundation: Prescription assistance for AML patients
  • Patient Advocate Foundation: Insurance appeals support

When to Escalate to State Regulators

Contact the Texas Department of Insurance if:

  • Cigna violates Texas appeal timelines
  • Step therapy overrides are inappropriately denied
  • External review requests are blocked
  • Coverage decisions appear to violate Texas insurance law

Texas Department of Insurance:

  • Phone: 1-800-252-3439
  • Website: tdi.texas.gov
  • IRO Information Line: 1-866-554-4926

Office of Public Insurance Counsel:

  • Phone: 1-877-611-6742
  • Provides consumer guidance on appeals process

Frequently Asked Questions

Q: How long does Cigna prior authorization take in Texas? A: Standard reviews are completed within 72 hours, expedited reviews within 24 hours. Submit complete documentation to avoid delays.

Q: What if Rezlidhia is non-formulary on my Cigna plan? A: Request a formulary exception with medical necessity documentation. Your oncologist must demonstrate that formulary alternatives are inappropriate or have failed.

Q: Can I request expedited review if my AML is progressing? A: Yes. Both Cigna internal appeals and Texas external reviews offer expedited pathways for urgent cases where treatment delays could jeopardize health.

Q: Does Texas step therapy protection apply to all Cigna plans? A: Only state-regulated plans (look for "TDI" on your insurance card). Federal employee plans, Medicare, and self-insured employer plans follow federal rules.

Q: What happens if I'm denied after external review? A: External review decisions are binding in Texas. If the IRO approves coverage, Cigna must comply. If denied, consider working with advocacy organizations to explore additional options.

Q: How much does Rezlidhia cost without insurance? A: Approximately $32,000 per month at list price. Manufacturer patient assistance programs may help reduce out-of-pocket costs during appeals.

Counterforce Health specializes in turning insurance denials into targeted, evidence-backed appeals for specialty medications like Rezlidhia. Their platform analyzes denial letters, identifies specific coverage criteria, and generates point-by-point rebuttals aligned with each payer's own policies—helping patients, clinicians, and specialty pharmacies navigate complex prior authorization requirements more effectively.

For additional support with your Cigna appeal, Counterforce Health's evidence-based approach can help strengthen your case by incorporating the right clinical citations and ensuring your submission meets all procedural requirements for Texas state-regulated plans.

Sources and Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance coverage decisions depend on individual plan terms and medical circumstances. Always consult with your healthcare provider and insurance company for guidance specific to your situation. Texas insurance laws apply only to state-regulated plans and may not cover federal employee plans, Medicare, or self-insured employer plans.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.